日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

更正:CircEAF2通过miR-BART19-3p/APC/β-catenin轴抑制Epstein-Barr病毒阳性弥漫性大B细胞淋巴瘤的进展。

Zhao, Chen-Xing; Yan, Zi-Xun; Wen, Jing-Jing; Fu, Di; Xu, Peng-Peng; Wang, Li; Cheng, Shu; Hu, Jian-da; Zhao, Wei-Li

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

反应适应性 zanubrutinib 和 tislelizumab 作为增强 CD19 CAR T 细胞疗法治疗复发/难治性大 B 细胞淋巴瘤的潜在策略:一项回顾性观察研究

Shen Rong, Cao Wei-Guo, Wang Li, Sheng Ling-Shuang, Zhang Yi-Lun, Wu Wen, Xu Peng-Peng, Cheng Shu, Liu Meng-Ke, Dong Yan, Wang Yue, Weng Xiang-Qin, Jiang Xu-Feng, Song Qi, Yi Hong-Mei, Li Lei, Chen Sheng, Yan Zi-Xun, Zhao Wei-Li

18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden

基于18F-FDG PET/CT指标对接受CAR-T细胞治疗的大B细胞淋巴瘤患者进行分层:免疫抑制性肿瘤微环境是高肿瘤负荷患者的负性预后指标

Sheng, Ling-Shuang; Shen, Rong; Yan, Zi-Xun; Wang, Chao; Zheng, Xin; Zhang, Yi-Lun; Yang, Hao-Xu; Wu, Wen; Xu, Peng-Peng; Cheng, Shu; Bachy, Emmanuel; Sesques, Pierre; Jacquet-Francillon, Nicolas; Jiang, Xu-Feng; Zhao, Wei-Li; Wang, Li

CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

CircEAF2通过miR-BART19-3p/APC/β-catenin轴抑制Epstein-Barr病毒阳性弥漫性大B细胞淋巴瘤的进展。

Zhao, Chen-Xing; Yan, Zi-Xun; Wen, Jing-Jing; Fu, Di; Xu, Peng-Peng; Wang, Li; Cheng, Shu; Hu, Jian-da; Zhao, Wei-Li

Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1/2 and biomarker study

地西他滨联合R-CHOP方案治疗新诊断弥漫性大B细胞淋巴瘤患者的临床疗效及肿瘤微环境影响:I/II期临床试验及生物标志物研究

Zhang, Mu-Chen; Fang, Ying; Xu, Peng-Peng; Dong, Lei; Shen, Rong; Huang, Yao-Hui; Fu, Di; Yan, Zi-Xun; Cheng, Shu; Jiang, Xu-Feng; Song, Qi; He, Yang; Zhao, Yan; Lu, Min; Ye, Jing; Liu, Feng; Cheng, Lin; Wang, Chao-Fu; Wang, Li; Zhao, Wei-Li

CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial

CEOP/IVE/GDP交替方案与CEOP方案作为一线治疗方案治疗新诊断的外周T细胞淋巴瘤患者的疗效比较:一项II期多中心随机对照临床试验的结果

Cai, Ming-Ci; Cheng, Shu; Wang, Xin; Hu, Jian-Da; Song, Yong-Ping; Huang, Yao-Hui; Yan, Zi-Xun; Jiang, Yu-Jie; Fang, Xiao-Sheng; Zheng, Xiao-Yun; Dong, Li-Hua; Ji, Meng-Meng; Wang, Li; Xu, Peng-Peng; Zhao, Wei-Li

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide

JAM-A 过表达与弥漫性大B细胞淋巴瘤的疾病进展相关,并可被来那度胺下调。

Xu, Peng-Peng; Sun, Yi-Feng; Fang, Ying; Song, Qi; Yan, Zi-Xun; Chen, Yi; Jiang, Xu-Feng; Fei, Xiao-Chun; Zhao, Yan; Leboeuf, Christophe; Li, Biao; Wang, Chao-Fu; Janin, Anne; Wang, Li; Zhao, Wei-Li

MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance

MicroRNA181a在T细胞白血病/淋巴瘤中过表达,且与化疗耐药性相关

Yan, Zi-Xun; Zheng, Zhong; Xue, Wen; Zhao, Ming-Zhe; Fei, Xiao-Chun; Wu, Li-Li; Huang, Li-Min; Leboeuf, Christophe; Janin, Anne; Wang, Li; Zhao, Wei-Li